VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | MRD as a tool to discontinue therapy in MM?

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses measurable residual disease (MRD) as a tool to discontinue therapy in multiple myeloma (MM). Dr Costa reveals that the next desired development in MM is to be able to use the dynamic prognostic information that MRD provides and repurpose it to make treatment decisions. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter